

Recd PCT/PTO 21 MAR 2005

(#3)

Appl. No: 10/518,110
Docket No: EX03-039C-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Canne, *et al.*
Application No.: 10/518,110
Filed: December 10, 2004
For: HUMAN ADAM-10 INHIBITORS

Confirmation No.: 3309
Attorney Docket No.: EX03-039C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant notes that Citation Nos. 8 and 9 of the Information Disclosure Statement in the attached PTO Form 1449 was first cited in the International Search Report (copy attached) from the International Searching Authority in the counterpart PCT application.

In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.

In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required, as the disclosure is submitted prior to the first office action on the merits. However, if this belief is in error, the Commissioner is authorized to charge any required fees to deposit account no. 50-1108.

Respectfully submitted,

Dated: March 17, 2005



Michael Atkins Reg. No. 35,431
EXELIXIS, INC.
170 Harbor Way, P.O. Box 511
South San Francisco, California 94083-0511
Telephone: (650) 837-8304
Facsimile: (650) 837-8234

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Canne, *et al.*
Application No.: 10/518,110
Filed: December 10, 2004
For: HUMAN ADAM-10 INHIBITORS

Confirmation No.: 3309
Attorney Docket No.: EX03-039C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The Chemical Abstracts Registry (CAS[®]) database was queried to identify structures that are identical or related to the structures recited in the claims of the above-referenced patent application. The following patent publications were identified:

EP0984959, MONSANTO CO, 2000-03-15
EP1202724, WARNER LAMBERT CO, 2002-05-08
EP1233016, WARNER LAMBERT CO, 2002-08-21
EP1233017, WARNER LAMBERT CO, 2002-08-21
EP1233018, WARNER LAMBERT CO, 2002-08-21
EP1279674, AMERICAN CYANAMID CO, 2003-01-29
EP1149072, HOFFMANN LA ROCHE, 2001-10-31
US6548524, AMERICAN CYANAMID CO, 2003-04-15
US6566384, DARWIN DISCOVERY LTD, 2003-05-20
US2003139414, PROCTER & GAMBLE, 2003-07-24
US2003166687, WARPEHOSKI ET AL, 2003-09-04
US5646167, CIBA GEIGY CORP, 1997-07-08
US5861510, PFIZER, 1999-01-19
US6506936, FIBROGEN INC, 2003-01-14
US6566381, PROCTER & GAMBLE, 2003-05-20
US6734183, ASTRAZENECA AB, 2004-05-11
US6734184, ASTRAZENECA AB, 2004-05-11
US2003139414, PROCTER & GAMBLE, 2003-07-24
US5753653, AGOURON PHARMA, 1998-05-19
US2003199520, BILLEDEAU et al., 2003-10-23
WO03082288, PROLIFIX LTD, 2003-10-09
WO02062756, PHARMACIA CORP, 2002-08-15
WO0063165, FUJISAWA PHARMACEUTICAL CO, 2000-10-26
WO0044739, ABBOTT LAB, 2000-08-03
WO02067866, AXYS PHARM INC, 2002-09-06
WO02062756, PHARMACIA CORP, 2002-08-15

Appl. No: 10/518,110
Docket No: EX03-039C


WO9808815, PROCTER & GAMBLE, 1998-03-05
WO9850348, AGOURON PHARMA, 1998-11-12
WO9640101, CIBA GEIGY AG, 1996-12-19


The above-references have not been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: March 17, 2005


Michael Atkins Reg. No. 35,431
EXELIXIS, INC.
170 Harbor Way, P.O. Box 511
South San Francisco, California 94083-0511
Telephone: (650) 837-8304
Facsimile: (650) 837-8234



Approved [redacted] through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

<i>Application Number</i>	10/518,110
<i>Filing Date</i>	12/10/2004
<i>First Named Inventor</i>	Canne
<i>Art Unit</i>	
<i>Examiner Name</i>	
<i>Attorney Docket Number</i>	EX03-039C-US

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁶ (if known)				
	1	WO9808825 /	3/5/98	THE PROCTER & GAMBLE CO.		
	2	WO9827069	6/25/98	SAWA PHARMACEUTICAL CO		
	3	WO9633172 /	10/24/96	PFIZER, INC		
	4	WO9834918 /	8/13/98	PFIZER, INC		
	5	WO0009492 /	2/24/00	PFIZER, INC		
	6	WO9958531 /	11/18/99	DUPONT PHARMACEUTICALS CO		
	7	WO9720824 /	6/12/97	AGOURON PHARMACEUTICALS, INC		
	8	US5753653	5/19/98	AGOURON PHARMACEUTICALS, INC		
	9	US6333324	12/25/01	FUJISAWA PHARMACEUTICAL CO.		

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PCT/PTO 21 MAR 2005

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/518,110
Filing Date	12/10/2004
First Named Inventor	Canne
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-039C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	LETAVIC et al, Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3243-6.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.